Research on new drugs in the therapy of bladder cancer (BC)
Journal Title: Advances in Hygiene and Experimental Medicine - Year 2018, Vol 72, Issue
Abstract
New, more effective and safer therapies in bladder cancer are being developed. Most attention is focused on monoclonal antibody therapies, targeted therapies and immunotherapy. Numerous pre-clinical and clinical studies on the use of the new drugs in bladder cancer are currently in progress. The great hope is associated with monoclonal antibodies, which are immune checkpoint inhibitors. Last year, two drugs from this group (Atezolizumab and Nivolumab) have been approved by Food and Drug Administration (FDA) for the treatment of muscle invasive bladder cancer (MIBC). Other monoclonal antibodies in this group such as Pembrolizumab are also in clinical trials. Much attention is also focused on targeted therapies. Inhibitors of: VEGF (vascular endothelial growth factor), EGFR (epidermal growth factor receptor), HER-2 (human epidermal growth factor receptor 2) and mTOR kinase are examined in bladder cancer. These drugs are often studied as a combination therapy with chemioterapeutic agents. Alternatives for BCG (Bacillus Calmette-Guérin) therapy in non muscle invasive bladder cancer (NMIBC) are also being developed. Research on the use of new vaccines and other immunotherapies (e.g. IL-12 therapy) are underway. The aim of this paper is to present the direction of current trends in bladder cancer treatment and what changes in therapy we can expect in the future. The drugs in clinical trials and those already registered in other countries have been reviewed. The latest drug-based therapeutic solutions have been described, which can replace traditional chemotherapy in the future.<br/><br/>
Authors and Affiliations
Karolina Jurkowska, Anna Długosz
Keywords
Related Articles
- EP ID EP346342
- DOI 10.5604/01.3001.0012.0539
- Views 151
- Downloads 0
Recognition of mycobacterial antigens by phagocytes
Recognition of mycobacterial antigens by receptors of phagocytes is not only a key element of the first line of defense, but also an important link to the specific phase of the immune response. The immune response is b...
Wpływ polimorfizmu genu MUC7 na stan uzębienia i higienę jamy ustnej u studentów Wydziału Stomatologii
Cel pracy: Celem pracy była ocena zależności pomiędzy polimorfizmem genu MUC7 a wskaźnikami PUWZ i PCR. Materiał/Metody: Badanie przeprowadzono wśród 158 studentów Wydziału Stomatologii PUM. Badanie kliniczne jamy ustnej...
The Clinical Course of Late Diagnosed Fatal Cases of A (H1N1) Influenza in Poland
Introduction: The most frequent complication of A (H1N1) influenza and the leading cause of death was pneumonia with a primary viral or mixed viral and bacterial etiology. 182 patients had died because of a pandemic infl...
Nieparzyste i rozgałęzione kwasy tłuszczowe w tłuszczu mlecznym – charakterystyka i właściwości prozdrowotne
W pracy przeanalizowano stan wiedzy na temat nieparzystych i rozgałęzionych kwasów tłuszczowych występujących w tłuszczu mlecznym. Zwrócono szczególną uwagę na charakterystykę, syntezę w organizmie przeżuwaczy, czynniki...
Selen w chorobie Gravesa-Basedowa
W pracy omówiono obecny stan wiedzy na temat roli selenu w chorobie Gravesa-Basedowa (Graves-Basedov’ disease – GBD). W ostatnim czasie, w patogenezie i przebiegu tej choroby, coraz więcej uwagi poświęca się zależności m...